- PMLive announced that the non-profit Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) will bring together scientists from MSKCC, Rockefeller University and Weill Cornell Medical College and will focus on basic research and early-stage drug discovery up to the ‘proof-of-concept’ stage.
- MSKCC’s Dr. Renier J. Brentjens was quoted in a New York Times article that outlined the impact that new immunotherapies have had on treating patients with melanoma, kidney, lung, breast, ovarian cancer and cancers of the colon, stomach, and head and neck.
- Dr. Peter Bach of MSKCC was quoted in a New York Times article about the soaring costs of prescription drugs.
- MSKCC’s vice president and CIO Patricia C. Skarulis and her colleagues commented on MSKCC’s data sources and strategies in Healthcare Informatics.